Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
A new survey from the supply-chain analysis company revals inefficiencies, inaccurate data and other flaws can be costly in terms of revenue, reputation and patient lives.
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
The GoGetTested response operating system, to date used to administer more than 200,000 tests, now will scale to include health systems in more states.
A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
The Medical Data Platform, an RPM solution from VivaLNK, handles clinical trials, cardiac monitoring, remote and in-patient monitoring and other tasks.
According to an executive from the drug development services company, pharma professionals should pay close attention to supply chain continuity and safety in the coming year.
A leader from the clinical trial solutions firm talks about the drive toward conducting trials without sites, and why that idea might lead to problems.
The head of the CRO’s Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.